Pharmaceutical companies developing treatments for children…

Pharmaceutical companies developing treatments for children with spinal muscular atrophy (SMA) commonly rely on standardized gross motor outcome measures to evaluate baseline function and monitor treatment effectiveness over time. Which of the following gross motor assessments is MOST commonly used in clinical trials and by drug manufacturers for children with SMA?